Archives
Nanoparticle Uptake in Human Corneal Epithelial Cells
Nanoparticle Uptake in Human Corneal Epithelial Cells
Topical ocular medicines are convenient, but their effectiveness is constrained by rapid precorneal clearance and limited penetration through the tear film and cornea. The study by Marjan Azadi and Allan E. David, published in ACS Biomaterials Science & Engineering, addresses a specific unresolved question: how do nanoparticle size and surface chemistry influence the mechanism of interaction with human cornea epithelial cells (HCECs)? The work is described in the reference study.
Study Background and Research Question
The ocular surface presents several sequential barriers. The tear film contains a superficial lipid layer and a mucoaqueous region enriched in mucin near the epithelial surface. Mucin can retain foreign materials through physical entrapment and chemical interactions, while continuous secretion and shedding contribute to clearance. Beneath this interface, the corneal epithelium is a tightly organized, stratified tissue with junctional complexes that restrict entry into deeper compartments.
Although viscosity modifiers, ointments, penetration enhancers, prodrugs, gels, and other formulation strategies can extend residence time or improve solubility, they may also cause irritation, inflammation, blurred vision, or systemic exposure. Polymeric nanoparticles offer a distinct approach because they can prolong surface retention, protect unstable cargo, regulate release, and potentially improve epithelial transport. PLGA is particularly useful because its formulation permits variation in size and surface properties while maintaining a broadly studied biodegradable polymer platform.
The central research gap was not simply whether nanoparticles enter corneal cells, but whether defined physicochemical features change how they enter. This distinction matters because a particle that remains attached to mucus may not be internalized efficiently, and high cellular association does not necessarily imply productive transcorneal delivery.
Key Innovation from the Reference Study
The main innovation was the controlled comparison of PLGA nanoparticles carrying different interfacial designs in an HCEC model that incorporated a simulated mucosal environment. The authors modified particle surfaces with alginate (ALG) and chitosan (CHS), selected for mucoadhesive behavior, and polyethylene glycol (PEG), selected for mucopenetrative behavior. This created a practical framework for comparing adhesion-oriented and mucus-transport-oriented designs rather than evaluating a single formulation in isolation.
The study also connected particle characterization with pathway analysis. Size, polydispersity, surface charge, cell viability, uptake, and inhibitor responses were considered together. That design is important because uptake differences can otherwise be misinterpreted: a larger particle may interact differently with mucus, a charged coating may alter membrane binding, and cytotoxicity may reduce apparent internalization simply by compromising cell health.
Rather than presenting nanoparticle uptake as a nonspecific process, the paper identifies a hierarchy of mechanisms. Energy dependence was established first, after which pathway-selective inhibitor experiments were used to distinguish macropinocytosis, caveolae-mediated endocytosis, clathrin-mediated endocytosis, and phagocytosis. The result is a more mechanistic contribution to ocular nanomedicine than a formulation screen based only on total fluorescence or endpoint association.
Methods and Experimental Design Insights
PLGA nanoparticles were produced using an emulsion-solvent evaporation method. Surface modification with ALG, CHS, or PEG was used to alter the particle interface while retaining PLGA as the core material. The resulting panel covered a meaningful range of particle sizes and zeta potentials. According to the reference study, the particles were spherical and monodisperse, with polydispersity indices below 0.2, sizes spanning approximately 100–250 nm, and zeta potentials from about −25 to +15 mV.
HCEC compatibility was evaluated with the MTT assay after 24 hours of nanoparticle exposure. The study reports only mild toxicity over the tested concentration range, with cell viability remaining approximately 70–100% at concentrations up to 100 μg/mL. This viability check is essential because pathway interpretation is difficult when an intervention or particle formulation causes substantial metabolic suppression.
For uptake experiments, the investigators used an HCEC monolayer integrated with a simulated mucosal solution. This model does not reproduce the complete human ocular surface, but it improves physiological relevance compared with a cell monolayer exposed directly to particles in a simple culture medium. Uptake was then evaluated across nanoparticle formulations, and inhibitor studies were used to assess the contribution of distinct internalization routes.
Protocol Parameters
- Particle platform: Use PLGA nanoparticles prepared by emulsion-solvent evaporation; the reference panel included unmodified and polymer-surface-modified particles.
- Surface chemistry: Compare ALG and CHS as mucoadhesive coatings with PEG as a mucopenetrative coating, while interpreting coating effects together with changes in charge and size.
- Particle attributes: The study evaluated spherical particles of approximately 100–250 nm, with zeta potentials near −25 to +15 mV and PDI values below 0.2; these values are reported in the paper.
- Cell-compatibility control: Include a 24-hour MTT assessment before assigning uptake differences to endocytic biology; the published study observed 70–100% viability up to 100 μg/mL.
- Ocular-interface model: Evaluate uptake using an HCEC monolayer with simulated mucosal solution rather than relying only on direct particle exposure in standard medium.
- Mechanism testing: Use energy-dependence and pathway-inhibitor controls together. In new experiments, verify inhibitor effects on viability and morphology because pathway inhibitors may have cellular actions unrelated to nanoparticle transport.
Core Findings and Why They Matter
The first major finding was that energy-dependent endocytosis was the primary uptake mechanism across the tested nanoparticle designs. This observation argues against passive diffusion as the dominant explanation for intracellular nanoparticle accumulation in the HCEC model. It also supports the use of mechanistic controls when interpreting uptake data from ocular epithelial systems.
Among the formulations, 100 nm PLGA nanoparticles and PEG-PLGA particles with a nominal size of 150 nm showed the highest HCEC uptake, as reported by the reference article. The result does not establish a universal optimum size. Instead, it suggests that uptake depends on the interaction between size, surface chemistry, mucus behavior, and the epithelial membrane. A smaller particle may encounter less steric resistance, whereas PEG may reduce nonspecific mucus entrapment and improve access to the cell surface.
Inhibitor experiments identified macropinocytosis and caveolae-mediated endocytosis as the dominant pathways within the tested conditions. Clathrin-mediated endocytosis contributed partially, while phagocytosis did not appear to play a meaningful role over the examined size and surface-chemistry ranges. These findings refine the design logic for topical ocular nanoparticles: improving mucus transport and epithelial contact may be more valuable than simply increasing mucoadhesive strength.
The mild toxicity profile strengthens, but does not prove, the biological interpretation. Because most formulations preserved substantial metabolic activity during the assay period, the uptake pattern is less likely to be explained solely by widespread cell injury. Nevertheless, MTT measures cellular metabolic activity rather than every aspect of barrier integrity, membrane trafficking, or long-term cell function. The most defensible conclusion is therefore that the tested PLGA systems were sufficiently compatible for short-term comparative uptake analysis.
For ocular drug delivery, the practical implication is a shift from a binary question—whether nanoparticles enter HCECs—to a multivariable optimization problem. Researchers should consider particle size and surface chemistry as coupled determinants of mucus interaction and endocytic routing. The study does not demonstrate improved delivery of a particular therapeutic payload in vivo, but it provides a rational basis for selecting formulations for subsequent permeability, retention, release, and efficacy studies.
Comparison with Existing Internal Articles
The internal overview Nanoparticle Uptake Pathways in Human Corneal Epithelial Cells summarizes the same central interpretation: energy-dependent uptake dominates, with macropinocytosis and caveolae-mediated endocytosis particularly important. Its value is as a concise pathway-oriented companion to the reference paper.
The reference study adds experimental depth by linking these pathways to a defined PLGA formulation panel, simulated mucosal conditions, particle characterization, and cytotoxicity measurements. In other words, the internal article is useful for orienting readers to the uptake mechanism, whereas the published work shows how physicochemical design variables were tested within an ocular epithelial model. Neither source should be read as proving that the same pathway balance will occur in intact human cornea or for every nanoparticle composition.
Limitations and Transferability
The model captures important epithelial interactions but remains an in vitro approximation. A HCEC monolayer with simulated mucosal solution does not reproduce the full tear-film dynamics, blinking, multilayered corneal architecture, stromal diffusion, immune surveillance, or vascular and lymphatic clearance. Consequently, high cellular uptake may not translate into deeper corneal penetration or improved ocular pharmacokinetics.
The formulation variables were also not completely independent. Changing a polymer coating can alter zeta potential, hydrodynamic diameter, hydration, mucus association, and membrane binding at the same time. This makes it difficult to assign every uptake difference to one molecular feature. Inhibitor studies provide useful pathway evidence, but inhibitor specificity, pathway overlap, and compensatory trafficking should be considered. Follow-up studies using orthogonal approaches—such as genetic perturbation, live-cell trafficking analysis, transcorneal models, and payload-specific release measurements—would strengthen causal interpretation.
Why this cross-domain matters, maturity, and limitations
Actin-dependent membrane remodeling is a plausible mechanistic bridge for future uptake studies, but the reference paper does not directly establish actin polymerization as the causal driver of the observed HCEC results. An actin polymerization inhibitor could therefore be used as one perturbation control, provided that morphology, viability, particle binding, and uptake are measured separately. This remains a hypothesis-testing extension rather than a conclusion from the ocular study.
Likewise, cell cycle arrest at G1-S transition, tumor cell proliferation inhibition, apoptosis induction in cancer cells, and viral transcription inhibition are distinct endpoints from corneal nanoparticle internalization. They should not be inferred from this paper or used as substitutes for ocular barrier experiments. The cross-domain connection is useful only when investigators clearly separate assay purpose, exposure conditions, and interpretation limits.
Research Support Resources
For researchers building a mechanistic uptake-control arm, Cytochalasin D (SKU B6645) can support separately optimized actin-perturbation workflows. Pair its use with vehicle, viability, morphology, and particle-association controls, and interpret it as a complementary tool rather than definitive proof of any single endocytic pathway.